entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 23:53:22 - browse：23

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Flu vaccine offering decent levels of protection this winter, new data show

leisure time

knowledge

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

An inside look at PIPEs, biotech's buzzy new financing tool

Health AI adoption puts security, privacy startups on investors' radar

In search for therapies for solid tumors, companies turn to claudin

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

In search for therapies for solid tumors, companies turn to claudin

hotspot

entertainment

leisure time

In age of alternative facts, a scholarly course on calling out crap

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

New air purifier tech could be key to improving indoor air quality

Physicians and social media: If you see something, say something?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

House looks to weaken Medicare negotiation

Continuity nursing helped my family in our darkest PICU moments

Positive childhood experiences can help future health

Novavax promises a turnaround & Lilly roils the obesity market

A Q&A with Aletha Maybank, AMA’s chief health equity officer

knowledge

House looks to weaken Medicare negotiation

Physicians and social media: If you see something, say something?

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Future doctors should be trained to promote social change

FogPharma raises $145 million in rare Series E round

leisure time

leisure time

knowledge

entertainment